Evinacumab-dgnb

(Evkeeza)

Evinacumab-dgnb

Drug updated on 11/15/2023

Dosage FormInjection (intravenous; 345 mg/2.3 mL (150 mg/mL), 1,200 mg/8 mL (150 mg/mL))
Drug ClassAngiopoietin-like 3 inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholesterolemia.

Product Monograph / Prescribing Information

Document TitleYearSource
Evkeeza (evinacumab-dgnb) Prescribing Information.2023Regeneron Pharmaceuticals, Inc., Tarrytown, NY

Systematic Reviews / Meta-Analyses

Document TitleYearSource
The promising novel therapies for familial hypercholesterolemia.2022Journal of Clinical Laboratory Analysis
Efficacy and safety of evinacumab for the treatment of hypercholesterolemia: a meta-analysis.2021Journal of Cardiovascular Pharmacology